DeFord John A 4/A
4/A · GLOBUS MEDICAL INC · Filed Sep 6, 2023
Insider Transaction Report
Form 4/AAmended
DeFord John A
Director
Transactions
- Award
Class A Common Stock
2023-09-01+15,578→ 15,578 total - Award
Stock Option (Right to Buy Class A Common Stock)
2023-09-01+15,000→ 15,000 totalExercise: $54.23Exp: 2033-09-01→ Class A Common Stock (15,000 underlying)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, NuVasive, Inc. ("NuVasive") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into NuVasive (the "Merger"), with NuVasive continuing as a wholly owned subsidiary of the Issuer. At the effective time of the Merger, each NuVasive restricted stock unit award was accelerated, cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Issuer, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of NuVasive common stock underlying such award.
- [F2]These options were granted on September 1, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on September 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
- [F3]The original Form 4, filed on September 6, 2023, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported an expiration date of September 1, 2024, when in fact such expiration date is September 1, 2033.